Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Oral idarubicin as a single agent therapy in patients with relapsed or resistant multiple myeloma.

Oral idarubicin as a single agent therapy in patients with relapsed or resistant multiple myeloma. Leuk Lymphoma. 1999 Nov; 35(5-6):593-7.

View in: PubMed

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.